Literature DB >> 7535931

Opposite effects of transforming growth factor alpha and epidermal growth factor on mouse placental lactogen I secretion.

M Yamaguchi1, L Ogren, H Kurachi, K Hirota, T Imai, F Talamantes.   

Abstract

This study was undertaken to determine whether transforming growth factor alpha (TGF-alpha) regulates the production of mouse placental lactogen I (mPL-I) and mPL-II in a manner that is similar to that of epidermal growth factor (EGF), which was previously shown to stimulate mPL-I secretion and inhibit mPL-II secretion. In contrast to the activity of EGF, human (h) and rat (r) TGF-alpha (each at 100 ng/ml) inhibited secretion of mPL-I by placental cells isolated from mice on day 7 of pregnancy. Maximum inhibition of mPL-I secretion occurred on the third day of a 5-day culture period and ranged between 37% and 56% in multiple trials. Incubation of cells with hTGF-alpha and EGF was not followed by a change in the mPL-I concentration of the medium, suggesting the peptides antagonized each other's effects. hTGF-alpha and rTGF-alpha inhibited secretion of mPL-II; maximum inhibition ranged between 62% and 84% in multiple trials. The lowest concentrations of hTGF-alpha that affected mPL-I and mPL-II secretion were 10 ng/ml and 1 ng/ml, respectively. EGF and hTGF-alpha bound to the same receptors on placental cells, as assessed by cross-linking, and both peptides stimulated receptor phosphorylation, as assessed by Western blot analysis. There are three types of mPL-containing cells in placental cultures: cells that contain only mPL-I, cells that contain only mPL-II, and cells that contain both mPLs. The percentage of each type of mPL-containing cell in the culture was determined by immunostaining. hTGF-alpha affected the differentiation of the subpopulations of PL-containing cells in a manner that differed from that of EGF. The data suggest that TGF-alpha and EGF do not regulate the production of mPL-I and mPL-II in a similar manner.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535931      PMCID: PMC42312          DOI: 10.1073/pnas.92.7.2830

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

Authors:  M Korc; J E Finman
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

2.  Changes in epidermal growth factor concentrations of submandibular gland, plasma and urine of normal and sialoadenectomized female mice during various reproductive stages.

Authors:  H Kurachi; T Oka
Journal:  J Endocrinol       Date:  1985-08       Impact factor: 4.286

3.  Biological, immunological, and binding properties of recombinant mouse placental lactogen-I.

Authors:  P Colosi; L Ogren; J N Southard; G Thordarson; D I Linzer; F Talamantes
Journal:  Endocrinology       Date:  1988-12       Impact factor: 4.736

4.  Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors.

Authors:  J M Siegfried
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

5.  Purification and partial characterization of two prolactin-like glycoprotein hormone complexes from the midpregnant mouse conceptus.

Authors:  P Colosi; L Ogren; G Thordarson; F Talamantes
Journal:  Endocrinology       Date:  1987-06       Impact factor: 4.736

6.  Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line.

Authors:  M Korc; C A Haussler; N S Trookman
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

7.  Distinct vascular actions of epidermal growth factor-urogastrone and transforming growth factor-alpha.

Authors:  B S Gan; M D Hollenberg; K L MacCannell; K Lederis; M E Winkler; R Derynck
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

8.  Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro.

Authors:  K J Ibbotson; J Harrod; M Gowen; S D'Souza; D D Smith; M E Winkler; R Derynck; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Developmental expression of transforming growth factors alpha and beta in mouse fetus.

Authors:  J N Wilcox; R Derynck
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

10.  Transforming growth factor alpha stimulates prostacyclin production by cultured human vascular endothelial cells more potently than epidermal growth factor.

Authors:  A Ristimäki
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

View more
  5 in total

1.  Cited1 is required in trophoblasts for placental development and for embryo growth and survival.

Authors:  Tristan A Rodriguez; Duncan B Sparrow; Annabelle N Scott; Sarah L Withington; Jost I Preis; Jan Michalicek; Melanie Clements; Tania E Tsang; Toshi Shioda; Rosa S P Beddington; Sally L Dunwoodie
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Regulation of mouse placental lactogen secretion by G proteins before midpregnancy.

Authors:  M Yamaguchi; A Miyake
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

3.  Lipopolysaccharides selectively inhibit mouse placental lactogen-II secretion through stimulation of interleukin-1 alpha (IL-1 alpha) and IL-6 production.

Authors:  M Yamaguchi; K Sawada; A Miyake
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

4.  Transforming growth factor-alpha regulates subpopulation of giant cells which secrete mouse placental lactogen-I (mPL-I) and/or mPL-II at midpregnancy.

Authors:  M Yamaguchi; K Ogura; M Sakata; A Miyake
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

5.  Regulation of mouse placental lactogen-II secretion by transforming growth factor-alpha after midpregnancy.

Authors:  M Yamaguchi; K Kobayashi; A Miyake
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.